News
The study found an increased risk of hypoglycemia with combination therapy, which decreased with prolonged use. Thiazolidinedione monotherapy was linked to higher mortality compared to GLP-1 RA ...
When a GLP-1 RA is prescribed along with insulin, it can increase the odds of hypoglycemia. Because GLP-1 RAs slow digestion, they may affect how some medications are absorbed. If you have ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
GLP-1 RA also significantly reduced the risk of ... (less than 0.1% for both), pancreatic cancer (0.2% for both), severe hypoglycemia (2.5% vs 2.3%), and retinopathy (3.2% for both) — did ...
Hosted on MSN6mon
GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD OutcomesThe GLP-1 RA and placebo groups had no differences in the risk for serious adverse events, including acute pancreatitis and severe hypoglycemia. "Taken together, these results and the breadth of ...
Study: Optimizing Nutrition, Diet, and Lifestyle Communication in GLP-1 Medication ... triggering hypoglycemia, helping reduce appetite and consequently body weight. However, GLP-1 RA therapy ...
The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18 percent lower risk for VTE ...
GLP-1 is an incretin hormone that helps regulate blood glucose levels after meals, acting in a glucose-dependent manner. This means it lowers blood sugar without causing hypoglycemia—a key ...
The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.
Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...
Twelve GLP-1 RA medications were studied, 3 that are FDA-approved (liraglutide, semaglutide, and tirzepatide) and 9 that are not yet approved for weight management. Treatment periods lasted from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results